Please assess the completion status of the following clinical trial:

Trial Title: Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A man or woman, aged 20 to 70, of any race who has had a heart or liver transplant~Exclusion Criteria:~* hyperparathyroidism~* Paget's disease~* hyperthyroidism~* cancer~* severe kidney disease,~* intestinal disease~* active peptic ulcer disease~* current or past treatment for osteoporosis~* pregnancy or lactation~* severe oral/dental disease

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Active Zoledronic Acid & Placebo Alendronate (Type: EXPERIMENTAL): Group 1 will receive an infusion of active zoledronic acid 5 mg during the first 4 weeks after transplantation. Placebo alendronate 70 mg once weekly will be initiated at the same time as the first zoledronic acid infusion.
- Placebo Zoledronic Acid & Active Alendronate (Type: EXPERIMENTAL): Group 2 will receive an infusion of placebo zoledronic acid during the first 5 weeks after transplantation. Active alendronate 70 mg once weekly will be initiated at the same time as the placebo infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).